Amgen

The golf lads, just to keep people up to speed.

Anyone who wasn't watching this opening round from the Amgen Irish Open yesterday.

So Joaquin Neiman is the man to catch after day one.

Five under a par round.

Myself, Enda and Dara in studio with you.

We will chat to John Bruin very shortly, but first let's check in with Tommy Rooney.

He has been down at Doonbeg for the Amgen Irish Open Day 1, heading into Day 2 now, of course, this morning.

Tommy, how are you keeping? Madness with the weather yesterday.

Like that's the way it goes.

Now, do bad things happen in good charts? Yeah, but they don't tend to compound upon themselves, right? So Amgen had a gap down this week.

actually looks pretty interesting to us here in the grand scheme of things.

So, you know, those are the things that we're looking for.

What are you hinting at there?

I'm hinting that there must be an explanation that maybe between DP, World Tour and Amgen, the sponsors,

they

maybe just didn't...

The Amgen Irish Open is the main show in town in County Clare at the moment.

The second day of action.

We're getting ready for that at Trump International in Doonbeg.

And good to see some Irish golfers in the mix as well in the shape of Shane Lowry.

and Roy McIlroy.

But we are returning to the Amgen Irish Open now and we're going to chat about all the work that's been going on behind the scenes and also the efforts to promote Doonbeg and the event itself.

And joining us now are Adrian Kelly, the Chief Fire Officer with Clare County Council and from Doonbeg Community Development, Jenny Drysdale.

A very good morning to both of you.

What if one of the biggest obstacles to treating rare diseases isn't the science, but the operating model we use to develop the medicine? My guest today is David Craig, co-founder, president, and CEO of Sarcomatrix Therapeutics.

David spent roughly three decades inside his companies including Amgen, Gilead, and Portola Pharmaceuticals, learning firsthand what decisions in drug development create value, which consume enormous amounts of capital, and where conventional pharmaceutical economics can actually prevent promising therapies from reaching patents, patients.

At Sarcometrics, David and his team are taking a very different approach.

Instead of thinking about muscle wasting conditions as completely separate diseases, they're looking at shared biology, starting with muscular dystrophy, where the mechanisms are particularly well understood and potentially extending into age-related muscle loss and the muscle loss increasingly associated with GLP-1 therapies.

And sitting there waiting to be harvested and brought forward for therapy.

And, and unfortunately politics gets involved in a lot of things.

And I think if I reflect back over the last 30 years, you know, back at Amgen back in the day, um, we're launching Epigen and it increases hematocrit, um, And where the initial indication was for dialysis patients, because the barrel receptor that tells your body to make more red blood cells is in your kidney.

So if you don't have any kidneys, you're chronically low blood cell, low red cell count.

I made some bad decisions in the last couple of days.

I bought some more Amgen, and Amgen fell off the face of the earth for whatever.

Amgen was solid.

No, man, they went down.

NCL and Carnival, their stocks have never been lower.

So Carmel, thanks very much for speaking to be here at the Amgen Irish Open just outside the Clare County Council tent here with a couple of local businesses inside.

Great to have them present here.

Oh, absolutely.

The Dow winners Apple, Alphabet, and Travelers.

The Dow decliners Caterpillar, Goldman Sachs, and Amgen.

The Dow down 317 points.

The Nasdaq lower by 172.